Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Sweet Spot" Inside Drug Benefit Turns Sour

This article was originally published in RPM Report

Executive Summary

The "donut hole" inside Part D is proving hard to fill. Some drug insurance plans offered brand coverage in 2006-but they won't be doing that again any time soon. Humana lost a mint offering "complete" coverage, so for now its generics-only in the gap.

You may also be interested in...



The Donut Hole Dilemma: Retaining Lost Patients Under Medicare Part D

Finally, some statistics about the impact of the Medicare Part D donut hole. The good news: drug manufacturers need not worry about most patients entering the coverage gap. The bad: a relatively large number of the industry's best customers do reduce their medication use in the donut hole-and if a customer is lost to the donut hole, they may be lost for good.

The Donut Hole Dilemma: Retaining Lost Patients Under Medicare Part D

Finally, some statistics about the impact of the Medicare Part D donut hole. The good news: drug manufacturers need not worry about most patients entering the coverage gap. The bad: a relatively large number of the industry's best customers do reduce their medication use in the donut hole-and if a customer is lost to the donut hole, they may be lost for good.

Building the Right Foundation: An Interview with Mark McClellan

The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel